Fiche société
Kissei Pharmaceutical Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| KDT-3594This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa. | Parkinson | Phase 2 | À vérifier | Japan | À vérifier |
| KDT-3594This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa. | Parkinson | Phase 2 | À vérifier | Japan | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| KDT-3594 | Parkinson | Phase 2 | NCT06722729 | A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||